Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Purchased by Vontobel Holding Ltd.

Vontobel Holding Ltd. boosted its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 51.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 10,600 shares of the company’s stock after buying an additional 3,600 shares during the period. Vontobel Holding Ltd.’s holdings in Harmony Biosciences were worth $342,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in HRMY. SG Americas Securities LLC acquired a new stake in Harmony Biosciences in the 3rd quarter worth about $667,000. State of Alaska Department of Revenue boosted its stake in Harmony Biosciences by 6.0% in the 3rd quarter. State of Alaska Department of Revenue now owns 20,919 shares of the company’s stock worth $685,000 after buying an additional 1,189 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in Harmony Biosciences by 10,091.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 40,561 shares of the company’s stock worth $1,329,000 after buying an additional 40,163 shares during the last quarter. Maryland State Retirement & Pension System raised its holdings in shares of Harmony Biosciences by 6.0% in the 3rd quarter. Maryland State Retirement & Pension System now owns 12,376 shares of the company’s stock worth $406,000 after purchasing an additional 697 shares during the period. Finally, Raymond James & Associates purchased a new position in shares of Harmony Biosciences in the 3rd quarter worth about $216,000. 86.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Harmony Biosciences

In other Harmony Biosciences news, insider Jeffrey Dierks sold 11,979 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $32.00, for a total transaction of $383,328.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 30.80% of the stock is owned by insiders.

Harmony Biosciences Stock Performance

Shares of NASDAQ:HRMY opened at $28.85 on Wednesday. The company has a market cap of $1.64 billion, a P/E ratio of 13.61, a PEG ratio of 0.41 and a beta of 0.73. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.72 and a current ratio of 2.75. Harmony Biosciences Holdings, Inc. has a one year low of $18.61 and a one year high of $39.26. The business’s 50-day simple moving average is $31.68 and its 200 day simple moving average is $30.01.

Harmony Biosciences (NASDAQ:HRMY) last announced its earnings results on Thursday, February 22nd. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.74 by ($0.29). Harmony Biosciences had a net margin of 22.16% and a return on equity of 27.49%. The company had revenue of $168.40 million for the quarter, compared to analysts’ expectations of $168.90 million. During the same quarter in the previous year, the business posted $1.01 earnings per share. The business’s quarterly revenue was up 31.3% compared to the same quarter last year. On average, sell-side analysts forecast that Harmony Biosciences Holdings, Inc. will post 3 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $49.00 price objective on shares of Harmony Biosciences in a report on Friday, April 12th. Bank of America restated an “underperform” rating and issued a $30.00 price objective on shares of Harmony Biosciences in a report on Tuesday, January 2nd. The Goldman Sachs Group raised their price objective on Harmony Biosciences from $25.00 to $28.00 and gave the stock a “sell” rating in a report on Tuesday, January 9th. Needham & Company LLC restated a “buy” rating and issued a $50.00 price objective on shares of Harmony Biosciences in a report on Tuesday, April 9th. Finally, Mizuho cut their price objective on Harmony Biosciences from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. Two investment analysts have rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat, Harmony Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $40.63.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.